| Press Releases

JP Kotha of Worldwide Clinical Trials to Present on Continuous Improvement Strategies for Bioanalytical Laboratories at AAPS 2024 PharmSci 360 Conference

Presentation to underscore global CRO’s leadership in continuous improvement, anchored in recent launch of WorldwideEdge™, customer satisfaction data, and continued growth

RESEARCH TRIANGLE PARK, N.C. – 21 OCTOBER 2024 – JP Kotha, Vice President, Bioanalytical Laboratory at Worldwide Clinical Trials, a global contract research organization (CRO), will present at the American Association of Pharmaceutical Scientists (AAPS) 2024 PharmSci 360 conference on Monday, 21 October, from 9:30-10:30 a.m. MT.

Kotha’s presentation, titled “Continuous Improvement in Bioanalytical Laboratories: Challenges and Success Stories,” will feature real-world case studies, uncovering the common pitfalls hindering continuous improvement (CI) implementation and celebrating the triumphs of embracing innovation for bioanalytical laboratory, and overall, success. Through Kotha’s presentation, audience members will discover how CI can fuel innovation, achieve operational excellence, and enhance quality – all while hearing firsthand how implementing CI initiatives has given Worldwide a distinct competitive edge in the industry, further positioning the CRO for continued growth.

“I am excited to share about Worldwide’s experiences in implementing continuous improvement programs within our bioanalytical laboratory,” said Kotha. “By focusing on innovation, operational excellence, and quality, we have been able to enhance our services and deliver exceptional results for our customers.”

In 2024, Worldwide launched WorldwideEdge™ – an initiative that embodies the CRO’s commitment to innovation and continuous improvement, ensuring its team operates at peak performance for every drug development program. The company’s steadfast focus on continuous improvement has led to impressive results such as 98% customer satisfaction, 95% on-time clinical dose delivery, and 93% bioanalytical accuracy on first attempt.

“Clinical trials are complex and often face high rates of non-success,” said Mike Mencer, Executive Vice President and General Manager, Early Phase at Worldwide. “That’s why sponsors need a CRO partner that is not only equipped to handle the intricacies of these programs but is also relentlessly pursuing better, more innovative ways to deliver results. At Worldwide, our teams provide personalized attention without compromising quality, and we are constantly striving to improve with a focus on enhancing operational performance, quality, and customer experience.”

To learn more, read this blog: WorldwideEdge™: Driving Innovation in Bioanalytical Lab Run Success Rates.

About Worldwide Clinical Trials:
Worldwide Clinical Trials (Worldwide) is a full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease. Its global footprint spans over 60 countries with more than 3,600 team members. For more information, visit www.worldwide.com.

Media Contact:
Jill Mastrangelo
Jill.Mastrangelo@Worldwide.com

Recent Press Releases

Resources

Our extensive collection of scientific articles and papers